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The challenging aim of cancer immunotherapy is to
selectively target the cellular destruction mechanisms of
the immune system towards malignant cells. Targeting
requires the specificity conferred by protein sequences that
are exclusively, or very selectively, expressed by tumor cells
and that are recognized by effector killer lymphocytes.
A tumor antigen can be defined as a biomolecule (most often
a protein) that is selectively expressed in malignant cells, is
presented through pathways of antigen presentation and is
recognized by killer T-cells. According to their expression
pattern, tumor antigens are divided into different groups:
(a) tumor-specific antigens, expressed only in neoplastic
cells and derived from altered self-proteins after gene
mutations, translocations or transcription of alternative
reading frames or from idiotypic proteins; (b) differentiation
antigens, expressed by tumor cells and by their untrans-
formed counterparts, although usually at lower levels;
(c) viral tumor antigens, associated with infections by viruses
causing cancer; and (d) cancer testis antigens, which are
expressed in a wide variety of tumors and in male germ line.
An important line of research aimed at the identification
of tumor antigens started several years ago with the
pioneering studies of Boon and colleagues [1]. Based on
an immunological/genetic approach, many of these antigens
were characterized by the use of T-cells as probes for
surrogate target cells into which gene libraries of tumor
cDNA had been transfected. Thus, in the P815 mouse tumor
model, this group characterized the P1A antigen by
stimulating a tumor-specific cytotoxic T-cell (CTL) clone
with target cells transfected with a cosmid library prepared
with the cDNA obtained from P815 mastocytoma cells.
Analysis of the cosmid sequence conferring susceptibility to
CTL recognition led to the identification of the gene
expressing the relevant tumor antigen [2]. Similarly, in
the case of human tumor antigens, the use of this genetic
approach allowed the identification of the gene MAGE-1,
encoding the antigen MZ2-E, and recognized by CTLs from
patient MZ2 suffering from melanoma [3]. Further charac-
terization showed that MAGE-1 belongs to a family of
related genes, all located on chromosome X. Analysis of the
expression of genes of the MAGE family has shown that
they are expressed in a wide variety of tumors, but not in
normal tissues, except for testicular germ cells and
occasionally placenta [4].
In the following years, through the use of new tumor-
specific CTL with different specificities and cDNA libraries
derived from tumors, mainly from melanomas, a high
number of tumor antigens have been identified. Some of
these new tumor antigens belong to the group of
cancer/testis antigens, since they show the same pattern of
expression as genes from the MAGE family. They include
genes of the BAGE, GAGE and PRAME families [5–7].
Besides the use of CTL as a searching tool, a new
technology based on the serological identification of
antigens by expression cloning has been developed. This
technology, called SEREX, has allowed the identification of
new antigens, many of them belonging to the cancer/testis
group, such as NY-ESO-1, HOM-TES-15/SCP-1 and HOM-
TES-85 [8]. With the SEREX technology it is the antibodies
present in the serum of cancer patients that are used as a
probe to recognize proteins selectively expressed in cancer
cells. An excellent correlation of antibody and T-cell-
recognized antigens has been found. Therefore some of
these antigens have been studied not only at the serological,
but also at the T-cell level, since they induce both humoral
and cellular immune responses. Among them, NY-ESO-1 is
the best characterized, and CTL and helper T-cell responses
against this antigen have been studied.
As mentioned earlier, genes of the MAGE family code
for proteins that encompass several antigenic peptides
capable of binding HLA class I or II molecules. These
complexes can be recognized by T lymphocytes on the
tumor cell surface. Since the MAGE genes encode antigens
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that are not expressed in normal tissues, they potentially
represent safe targets for cancer immunotherapy. This has
led to the use of these antigens as immunogens in clinical
trials. Most of these early clinical trials using MAGE-
derived antigens have enrolled melanoma patients.
Synthetic peptides encompassing CTL epitopes derived
from MAGE proteins have been the immunogens preferen-
tially used. Patients were immunized directly with the CTL
epitope peptides, in order to induce anti-tumor CTL
responses [9,10]. Due to the important role of CD4 T-cells
in the induction of CTL responses [11], some immunization
protocols have also included the CD4 T-cell epitopes,
mainly peptides able to be presented by a wide number of
HLA class II molecules [12]. In general, these immunization
protocols have been able to induce CTL responses in some
patients, and minor clinical effects were reported.
Preclinical experiments have demonstrated that
dendritic cells (DC) are professional antigen presenting
cells (APC) specialized in immune response induction
[13,14]. In the case of tumors, it has been shown that
immunization with these APC can break the tolerant status
against tumor antigens. For this reason, subsequent
immunization protocols using peptides from tumor antigens
have administered the antigens pulsed onto DC [15–18]. In
these cases, clear responses against immunizing antigens
have been detected, together with some clinically relevant
results that unfortunately were not curative. Similarly to the
immunization of MAGE peptides in adjuvant, immuniz-
ation with peptides using DC have been carried out using
CTL epitopes in conjunction with T-helper epitopes, both
belonging to tumor antigens [19]. Recently, a new
vaccination protocol against MAGE antigens has been
reported, using MAGE 3 protein instead of peptides, aimed
at inducing both CTL and T-helper responses [20]. For other
CTL-recognized epitopes, including some on melanoma
antigens, an effort has been made to improve their
immunogenicity. This is achieved by selecting mutations
that are cross-reactive with the original sequence but with
higher affinity for the HLA presenting molecule and/or the
antigen T-cell receptor. When successful, these strategies
produce peptides with clearly superior therapeutic activity
in vaccination protocols [21]. In the case of MAGE
antigens, there is no report of such improved peptide and
the approach could potentially enhance efficacy.
As mentioned earlier, antigens of the MAGE family were
characterized in melanoma, but they are also expressed in
other tumors. Akin to other cancer/testis antigens, MAGE
antigens are expressed in tumors such as breast carcinomas,
gliomas, head and neck carcinomas, non-small cell lung
tumors, colorectal carcinomas, and others. This finding has
prompted some researchers to use these antigens in clinical
trials against MAGE-expressing tumors different from
melanoma [22]. In recent years, expression of MAGE
antigens in hepatocellular carcinoma (HCC) has been
studied, and several groups have reported an expression of
different MAGE proteins in hepatic cancer cell lines as well
as in tumor samples obtained from patients [23]. Thus,
MAGE antigens have also become a new attractive target
for the treatment of this kind of tumor.
Cloning and identification of MAGE antigens stemmed
from the fact that some melanoma patients had an expansion
of T-lymphocytes recognizing the antigenic peptides [1].
This finding is in line with a tumor-specific immune
response in cancer patients, probably resulting from cross-
presentation of tumor antigens by endogenous professional
APC [24].
In this issue of the Journal, Zerbini et al. [25] show
evidence indicating that the patients suffering from HCC
have intratumoral and possibly circulating effector/memory
lymphocytes with specificity for MAGE antigens. RT-PCR
analysis has conclusively demonstrated that mRNA encod-
ing MAGE-1 and MAGE-3 is a common feature in HCC. At
least in their series of 20 cases, 17 expressed either MAGE-
1 (85% of cases) or MAGE-3 (45% of cases). Those results,
that were confirmed by immunohistochemistry, highlight
the frequency of such antigens in HCC in agreement with a
previous report [23].
Tumor lymphocyte infiltration was studied in biopsy
samples of cases with clear evidence of accumulation of
CD8 þ T lymphocytes that importantly, were devoid of
perforin, and thus ineffective at carrying out cytotoxicity, at
least by means of this effector molecule. Previous studies
correlated the intensity of lymphocyte infiltration with a
better prognosis in some malignancies [26] and similar
prospective studies should be extended to HCC.
Lymphocytes from some patients were studied with HLA
tetramers. These are multimers of folded HLA class I
molecules bound to antigenic peptides that can detect
T lymphocytes expressing specific T-cell receptors. The
authors selected MAGE-1 and MAGE-3 peptides that have
been described to be immunogenic when presented by
HLA-A1 and HLA-A2 molecules [27]. Using these HLA
tetramers as a probe, they were able to detect MAGE-
specific lymphocytes in two out of 10 cases studied.
Using antigen stimulation in culture with peptides and a
cocktail of cytokines, they were able to obtain some
expansion of MAGE-specific CD8 þ T-cells in two other
cases. Importantly and intriguingly, in one patient
(patient 10) with high baseline levels of MAGE-1-specific
lymphocytes, in vitro stimulation resulted in a drop of
specific T-cells. This is reminiscent of the situation reported
in melanoma patients whose lymphocytes, specific for
MART-1 and tyrosinase, showed partial unresponsiveness
in spite of being relatively abundant at baseline [28]. Like in
the case of Zerbini et al. [25], most functional studies have
been performed on single cases with unusually abundant
tumor-specific lymphocytes and this makes us wonder
whether we are only concentrating on exceptional cases.
Indeed, as a consequence of technical limitations, Zerbini
et al. studied in depth only one HCC case characterized by a
dense infiltration of MAGE-specific T lymphocytes. MAGE-
1-specific T lymphocytes from that case had the surface
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phenotype of effector/memory T lymphocytes. Unfortu-
nately, their specific lytic activity could not be tested directly
ex vivo, but the lack of perforin expression suggests that they
were ill-equipped at carrying out cytolytic functions. We
cannot exclude, however, that a significant number of tumor
cells are destroyed through perforin-independent mechan-
isms (TRAIL, FAS-L, cytokines). Upon in vitro re-
stimulation, those lymphocytes displayed cytotoxic and
IFN-g secretion abilities. In summary, results by Zerbini et al.
are interesting but should be taken with caution because, as
mentioned, most of their observations were made on a single
patient with a high proportion of tumor reactive T-cells.
HCC is one of the most difficult tumors to treat and its
incidence has been steadily rising. Surgery is the only
curative option, but less than one-third of these patients are
good candidates. Moreover, 5-year recurrence of HCC after
surgery is around 50–75% depending on the series.
Therefore, the idea of MAGE-1 and MAGE-3 being
potentially immunogenic in HCC patients opens two
avenues for immunotherapy: (i) active vaccination, or/and
(ii) adoptive T-cell therapy with ex vivo expanded
T-lymphocytes.
Evidence for T-cell reactivity after injection of dendritic
cells pulsed with MAGE antigens has been reported in
melanoma [15–18]. This has been the most powerful
approach so far to active immunization, but there is ample
scope for improvement since most tumors progressed with
little practical therapeutic impact. Vaccination has been also
tried with synthetic antigenic peptides, even without
adjuvant, with evidence of some clinical activity but with
unremarkable T-cell responses [10].
Adoptive T-cell therapy is gaining support in tumor
therapy also, because techniques to select and expand
T-cells in culture have improved. Patients with HCC
undergoing adoptive transfer with mitogen-activated
T-cells experienced much fewer relapses post-surgery than
untreated controls [29]. Thus, the more specific MAGE-
based immunotherapy has a potential role in eliminating
micrometastatic disease and reducing tumor recurrence
following surgery or ablative procedures.
In melanoma, pretreatment with non-myeloablative
chemotherapy regimes increased the efficacy of reinfused
pre-activated T-cells which undergo a vast expansion in
vivo with resultant clinical efficacy in some patients [30].
Chemotherapy regimes are supposed to eliminate suppres-
sor T-cells and/or competitors for scarce T-cell growth
factors such as interleukins 7 and 15 [30].
Adoptive T-cell therapy using a single T-cell determi-
nant seems to be less effective than using polyclonal T-cells
covering various specificities [30,31]. The main reason
seems to be that T-cells escape immunotherapy by down-
regulating the expression of antigen or antigen-presenting
molecules [31]. Therefore search for other shared tumor
antigens should continue in HCC. Apart from a polyclonal
effector population, adoptive T-cell therapy will also benefit
from de-bulking strategies that would both reduce tumor
mass and lessen the effect of tumor factors detrimental to the
immune system.
A combination of active immunization with a mixture of
antigens followed by reinfusion of ex vivo expanded T-cells
is, in our opinion, the most promising route ahead. The
results by Zerbini et al. suggest that this approach may be
feasible in a significant percentage of HCC patients. They
also speculate that the HCC tissue may harbor factors that
maintain T-cells anergic, and thus unable to attack
malignant cells. The paradox of finding an expanded
lymphocyte population infiltrating HCC along with con-
comitant disease progression deserves more attention in
order to understand the mechanisms involved.
In conclusion, the discovery of a suitable molecular
antigenic target in HCC should help in devising new
immunotherapeutic strategies; these in turn could benefit
patients, who very often lack any other treatment options.
Acknowledgements
Drs Borra´s, Prieto, Bendandi and Lasarte are acknowl-
edged for scientific discussion. We are grateful to Dr Diego
Vergani for critical reading and English editing. Financial
support was granted from MCYT (SAF02/0373 and
SAF01/1119), Gobierno de Navarra (Departamento de
Salud) and Redes Tema´ticas de Investigacio´n Cooperativa
FIS (RETICs C03/10 and C03/02).
References
[1] Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel
A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol
1994;12:337–365.
[2] Van den Eynde B, Lethe B, Van Pel A, De Plaen E, Boon T. The gene
coding for a major tumor rejection antigen of tumor P815 is identical
to the normal gene of syngeneic DBA/2 mice. J Exp Med 1991;173:
1373–1384.
[3] van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E,
Van den Eynde B, et al. A gene encoding an antigen recognized by
cytolytic T lymphocytes on a human melanoma. Science 1991;254:
1643–1647.
[4] Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis
antigens: an expanding family of targets for cancer immunotherapy.
Immunol Rev 2002;188:22–32.
[5] Boel P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P,
et al. BAGE: a new gene encoding an antigen recognized on human
melanomas by cytolytic T lymphocytes. Immunity 1995;2:167–175.
[6] Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon
T. A new family of genes coding for an antigen recognized by
autologous cytolytic T lymphocytes on a human melanoma. J Exp
Med 1995;182:689–698.
[7] Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, de Smet C,
et al. Characterization of an antigen that is recognized on a melanoma
showing partial HLA loss by CTL expressing an NK inhibitory
receptor. Immunity 1997;6:199–208.
[8] Tureci O, Sahin U, Pfreundschuh M. Serological analysis of human
tumor antigens: molecular definition and implications. Mol Med
Today 1997;3:342–349.
P. Sarobe et al. / Journal of Hepatology 40 (2004) 155–158 157
[9] Reynolds SR, Oratz R, Shapiro RL, Hao P, Yun Z, Fotino M, et al.
Stimulation of CD8 þ T cell responses to MAGE-3 and Melan A/
MART-1 by immunization to a polyvalent melanoma vaccine. Int J
Cancer 1997;72:972–976.
[10] Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier
MH, et al. Tumor regressions observed in patients with metastatic
melanoma treated with an antigenic peptide encoded by gene MAGE-
3 and presented by HLA-A1. Int J Cancer 1999;80:219–230.
[11] Lasarte JJ, Sarobe P, Gullon A, Prieto J, Borras Cuesta F. Induction of
cytotoxic T lymphocytes in mice against the principal neutralizing
domain of HIV-1 by immunization with an engineered T-cytotoxic-T-
helper synthetic peptide construct. Cell Immunol 1992;141:211–218.
[12] Weber JS, Hua FL, Spears L, Marty V, Kuniyoshi C, Celis E. A phase
I trial of an HLA-A1 restricted MAGE-3 epitope peptide with
incomplete Freund’s adjuvant in patients with resected high-risk
melanoma. J Immunother 1999;22:431–440.
[13] Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo
LD, et al. Bone marrow-derived dendritic cells pulsed with synthetic
tumour peptides elicit protective and therapeutic antitumour immu-
nity. Nat Med 1995;1:1297–1302.
[14] Dhodapkar MV, Steinman RM, Sapp M, Desai H, Fossella C,
Krasovsky J, et al. Rapid generation of broad T-cell immunity in
humans after a single injection of mature dendritic cells. J Clin Invest
1999;104:173–180.
[15] Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P,
Jonuleit H, et al. Vaccination with mage-3A1 peptide-pulsed mature,
monocyte-derived dendritic cells expands specific cytotoxic T cells
and induces regression of some metastases in advanced stage IV
melanoma. J Exp Med 1999;190:1669–1678.
[16] Mackensen A, Herbst B, Chen JL, Kohler G, Noppen C, Herr W, et al.
Phase I study in melanoma patients of a vaccine with peptide-pulsed
dendritic cells generated in vitro from CD34(þ) hematopoietic
progenitor cells. Int J Cancer 2000;86:385–392.
[17] Toungouz M, Libin M, Bulte F, Faid L, Lehmann F, Duriau D, et al.
Transient expansion of peptide-specific lymphocytes producing IFN-
gamma after vaccination with dendritic cells pulsed with MAGE
peptides in patients with mage-A1/A3-positive tumors. J Leukoc Biol
2001;69:937–943.
[18] Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N,
Rolland A, et al. Immune and clinical responses in patients with
metastatic melanoma to CD34(þ) progenitor-derived dendritic cell
vaccine. Cancer Res 2001;61:6451–6458.
[19] Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S,
Woerl P, et al. Rapid induction of tumor-specific type 1 T helper cells
in metastatic melanoma patients by vaccination with mature,
cryopreserved, peptide-loaded monocyte-derived dendritic cells.
J Exp Med 2002;195:1279–1288.
[20] Marchand M, Punt CJ, Aamdal S, Escudier B, Kruit WH, Keilholz U,
et al. Immunisation of metastatic cancer patients with MAGE-3
protein combined with adjuvant SBAS-2: a clinical report. Eur J
Cancer 2003;39:70–77.
[21] Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola
FM, Topalian SL, et al. Immunologic and therapeutic evaluation of a
synthetic peptide vaccine for the treatment of patients with metastatic
melanoma. Nat Med 1998;4:321–327.
[22] Sadanaga N, Nagashima H, Mashino K, Tahara K, Yamaguchi H,
Ohta M, et al. Dendritic cell vaccination with MAGE peptide is a novel
therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res
2001;7:2277–2284.
[23] Yamashita N, Ishibashi H, Hayashida K, Kudo J, Takenaka K, Itoh K,
et al. High frequency of the MAGE-1 gene expression in
hepatocellular carcinoma. Hepatology 1996;24:1437–1440.
[24] Arina A, Tirapu I, Alfaro C, Rodriguez-Calvillo M, Mazzolini G,
Inoges S, et al. Clinical implications of antigen transfer mechanisms
from malignant to dendritic cells. Exploiting cross-priming. Exp
Hematol 2002;30:1355–1364.
[25] Zerbini A, Pilli M, Soliani P, Ziegler S, Pelosi G, Orlandini A, et al.
Ex vivo characterization of tumor-derived melanoma antigen
encoding gene-specific CD8 þ cells in patients with hepatocellular
carcinoma. J Hepatol 2004;40:102–109.
[26] Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M,
Regnani G, et al. Intratumoral T cells, recurrence, and survival in
epithelial ovarian cancer. N Engl J Med 2003;348:203–213.
[27] Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human
tumor antigens recognized by T cells. Cancer Immunol Immunother
2001;50:3–15.
[28] Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, et al.
Characterization of circulating T cells specific for tumor-associated
antigens in melanoma patients. Nat Med 1999;5:677–685.
[29] Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T,
Yamamoto J, et al. Adoptive immunotherapy to lower postsurgical
recurrence rates of hepatocellular carcinoma: a randomised trial.
Lancet 2000;356:802–807.
[30] Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the
treatment of patients with cancer. Nat Rev Cancer 2003;3:
666–675.
[31] Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, et al.
Adoptive T cell therapy using antigen-specific CD8 þ T cell clones
for the treatment of patients with metastatic melanoma: in vivo
persistence, migration, and antitumor effect of transferred T cells.
Proc Natl Acad Sci USA 2002;99:16168–16173.
P. Sarobe et al. / Journal of Hepatology 40 (2004) 155–158158
